OSTX · OS Therapies Inc
$1.71
+0.05 (+3.01%)
At close · Sep 2
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$76.57M
Shares
46.13M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Paul A. Romness | MPH President and Chief Executive Officer | $1,942,168 |
| Robert G. Petit | Chief Medical and Scientific Officer | $1,030,000 |
| Christopher P. Acevedo | Chief Financial Officer | $280,000 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Paul A. Romness | MPH President and Chief Executive Officer | $3,434,316 |
| Robert G. Petit | Chief Medical and Scientific Officer | $665,046 |
| Christopher P. Acevedo | Chief Financial Officer | $158,523 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Paul A. Romness | MPH President and Chief Executive Officer | $360,000 |
| Robert G. Petit | Chief Medical and Scientific Officer | $300,000 |
| Christopher P. Acevedo | Chief Financial Officer | $36,000 |
Key facts
CIK
1795091
CUSIP
68764Y207
13F (30d)
27 filings
27 filers
Visit website
Investor relations